| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Nitrogen-containing bisphosphonates (N-BPs) have greater anti-bone-resorptive effects than non-nitrogen-containing BPs (non-N-BPs). However, N-BPs have side effects including osteonecrosis of the jaw. In the present study, we obtained the following results. (i) Minodronate, an N-BP produced in Japan, has inflammatory/necrotic side effects (INSEs) in mice. (ii) Lipopolysaccharide (LPS) of bacterial cell wall markedly exacerbates INSEs of N-BPs at the site of injection. (iii) N-BPs, irrespective of their side chain structures, are taken within cells via the phosphate transporters SLC20/34 and induce INSEs. (iv) We previously found that etidronate (Eti, a non-N-BP) could prevent and/or reduce the inflammatory/necrotic effects of N-BPs, and that Eti could replace N-BPs that had already bound to bones, leading us to propose “Eti-replacement therapy”. In the present study on patients with osteonecrosis of the jaw, we obtained effective results of the therapy.
|
